West Nile Virus (WNV) Antibody, IgG and IgM, CSF
West Nile Virus is a member of family Flaviviridae (genus Flavivirus) and the causative agent of West Nile fever and West Nile encephalitis. The virus gets its name from the West Nile region of Uganda where it was first isolated. Since 1999, West Nile virus outbreaks are being reported every year during late summer to early fall.
West Nile virus is an enzootic virus and typical reservoirs include a variety of birds, both wild and domestic. Upon infection, the birds show significant viremia and become potentially infectious. Culex mosquitoes that feed on the blood of these birds serve as vectors for bird-to-bird transmission. Humans and other mammals are accidental and "dead end" hosts in that the viremia in people is insufficient in quantity to allow mosquitoes to transmit the virus from humans to other humans or animals. Human-human and human-mammal transmissions by vectors are not reported. Rare cases of human-to-human transmission through blood transfusion and organ donation have been documented in the literature resulting in testing for West Nile virus as part of universal screening for blood and organ donors.
The majority of human infections (75-80%) are asymptomatic and sub-clinical. A fifth of the cases become febrile and show symptoms of viral infection, viz. headache, nausea, joint pain, rashes and body aches. Less than 1% of individuals develop meningitis, encephalitis or both. The risk is higher amongst children, elderly and immunocompromised individuals such as patients with chronic liver/kidney disease, malignancies and organ transplant recipients. Deaths due to West Nile virus infections are usually associated with severe co-morbidities. Autopsy studies have shown damage in the anterior horn of the spinal cord, brain stem and cranial nerves, dorsal root ganglia and sympathetic ganglia.
After an incubation period of 8-14 days, most individuals show IgM antibodies in the serum and cerebrospinal fluid that persist for about one to two months. IgG antibodies appear three weeks after infection and persist for about 500 days or longer. Since viremia is insignificant, detection of viral particles by nucleic acid amplification tests and viral culture of serum, CSF or brain tissue lacks sensitivity and limits clinical utility of these tests.
In addition to ELISA serology testing, Nucleic Acid Testing is the most sensitive and is used for donor testing and for confirmation of infection.
- Diagnosis of West Nile fever/West Nile encephalitis
- Confirm infection with West Nile Virus
- Donor screening (must be FDA approved of donor screening)
- IgM antibodies can be reliably demonstrated in the serum and CSF by IgM-capture enzyme linked immunosorbant assay (ELISA) during the stage of acute illness.
- Detection of IgM in the CSF often signifies an active neurological infection, since IgM in the serum cannot cross the blood brain barrier.
- WNV Nucleic acid detection by PCR is recommended for confirmation and treatment
- Interpretation of ELISA and other serological tests needs clinical correlation to avoid two common pitfalls, viz. cross-reacting antibodies and persistent antibodies. IgM antibodies directed against other viruses of flaviviridae (St. Louis encephalitis virus, dengue virus etc.) as a result of infection or vaccination often cross-react with anti-WNV IgM antibodies.
- Interference by cross-reacting antibodies can be overcome by plaque reduction neutralization tests (offered by local and state health departments).
Negative (Non-reactive)
Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Cerebrospinal fluid collected in a sterile container or tube.
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Am J Health Syst Pharm. 2004 Jun 15;61(12):1235-41. [PMID: 15259752]
- Clin Infect Dis. 2006 Jun 1;42(11):1527-35. [PMID: 16652309]
- N Engl J Med. 2001 Jun 14;344(24):1807-14. [PMID: 11407341]
- Ann Intern Med. 2002 Aug 6;137(3):173-9. [PMID: 12160365]